uniQure N.V. (QURE)

NASDAQ: QURE · IEX Real-Time Price · USD
18.57
-0.10 (-0.54%)
At close: Jun 28, 2022 4:00 PM
18.50
-0.07 (-0.38%)
After-hours: Jun 28, 2022 7:58 PM EDT
-0.54%
Market Cap 866.25M
Revenue (ttm) 525.34M
Net Income (ttm) 324.47M
Shares Out 46.65M
EPS (ttm) 6.89
PE Ratio 2.70
Forward PE 27.93
Dividend n/a
Ex-Dividend Date n/a
Volume 927,026
Open 18.81
Previous Close 18.67
Day's Range 18.54 - 19.17
52-Week Range 12.52 - 38.80
Beta 1.12
Analysts Buy
Price Target 56.28 (+203.1%)
Earnings Date Jul 25, 2022

About QURE

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatm... [Read more...]

Industry Biotechnology
IPO Date Jun 20, 2007
Employees 463
Stock Exchange NASDAQ
Ticker Symbol QURE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for QURE stock is "Buy." The 12-month stock price forecast is 56.28, which is an increase of 203.07% from the latest price.

Price Target
$56.28
(203.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

uniQure (QURE) Up on Safety Data From Huntington's Disease Study

uniQure (QURE) posts safety and biomarker data from the 10 patients enrolled in the lower-dose cohort of its ongoing phase I/II study evaluating AMT-130 for treating Huntington's disease.

uniQure (QURE) Moves 27% Higher: Will This Strength Last?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

UniQure Shares Are Up After Low-Dose Cohort Data From Huntington's Gene Therapy Trial

UniQure N.V. (NASDAQ: QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2 trial of AMT-130 gene therapy for Huntington's disease.

Why uniQure's Stock Price Jumped Today

It just reported a packet of promising safety data for its flagship pipeline program.

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of...

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~

CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ: QURE), please note that all the numb...

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

Mizuho Comments On UniQure's Upcoming Low-Dose Huntington's Gene Therapy Trial Data

The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time. The initial results from the first fou...

uniQure Announces FDA Acceptance of Biologics License Application for Etranacogene Dezaparvovec under Priority Review

If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B If approved, etranacogene dezaparvovec would be the first gene therapy option for people...

FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review

-- If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B -- This milestone underscores CSL Behring's promise to develop and deliver a truly un...

uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, to...

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

~ Partner CSL Behring submitted Marketing Authorization Application (MAA) in Europe for etranacogene dezaparvovec in hemophilia B; MAA validated by the European Medicines Agency (EMA) and granted accele...

uniQure (QURE) Stock Jumps 8.1%: Will It Continue to Soar?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with ...

Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with hemophil...

uniQure (QURE) Moves 5% Higher: Will This Strength Last?

uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-1...

LEXINGTON, Mass. and AMSTERDAM, March 21, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

UniQure (QURE) Tops Q4 Earnings and Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of 123.61% and 129.68%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress

~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX prophyla...

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntingto...

LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, t...

3 High Return Non-Cyclical Stocks

Investors may want to consider the following non-cyclical stocks, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are outperforming the 20-year high-quality mar...

Other symbols: KOSBS

After Plunging 33.5% in 4 Weeks, Here's Why the Trend Might Reverse for uniQure (QURE)

The heavy selling pressure might have exhausted for uniQure (QURE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r...

uniQure (QURE) Upgraded to Buy: Here's Why

uniQure (QURE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

uniQure (QURE) Falls on Data From Huntington's Disease Study

uniQure (QURE) reports initial data on the first four patients enrolled in the lower-dose cohort of its ongoing phase I/II clinical trial of AMT-130 for treating Huntington's disease.

UniQure Shares Fall After Clinical Update From Huntington's Disease Gene Therapy Trial

UniQure NV (NASDAQ: QURE) announced initial observations on the first four patients enrolled in the lower-dose cohort of Phase 1/2 trial of AMT-130 for Huntington's disease.  AMT-130 was generally well ...